Showing all 2 results
Furosemide & Spironolactone Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical stability of both active pharmaceutical ingredients.
Active Ingredient Strength Primary Clinical Function Furosemide USP/Ph.Eur. 20 mg The Loop Diuretic (Fluid Clearance): Rapidly eliminates severe fluid buildup (edema) from the lungs, abdomen, and peripheral tissues. Spironolactone USP/Ph.Eur. 50 mg The Potassium-Sparing Shield: Blocks aldosterone, prevents toxic cardiac fibrosis, and heavily protects the patient against lethal hypokalemia. Excipients Microcrystalline Cellulose / Lactose Monohydrate / Sodium Starch Glycolate / Povidone K-30 / Magnesium Stearate / Premium Polymeric Film Diluent / Binder / Superdisintegrant / Slipper-Coating (Engineered utilizing advanced wet-granulation to ensure both the rapid-acting Furosemide and the slower-acting Spironolactone dissolve at precise, synchronized rates to guarantee the electrolyte-sparing synergy) *Pack Sizes: 10×10 Blisters (Optimized specifically for strict chronic cardiology and hepatology dispensing regimens).
L- ornithine-L-aspartate tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical and physical stability of the highly hygroscopic amino acid salt.
Active Ingredient Strength Primary Clinical Function L-Ornithine L-Aspartate (LOLA) 150 mg / 250 mg Hepatology Maintenance Standard: Base therapeutic units for long-term chronic management of severe Non-Alcoholic Fatty Liver Disease (NAFLD), alcoholic hepatitis, and mild hyperammonemia. L-Ornithine L-Aspartate (LOLA) 500 mg Acute Detoxification Standard: High-efficacy adult therapy utilized for immediate ammonia reduction and the step-down management of Hepatic Encephalopathy following hospital discharge. Excipients Microcrystalline Cellulose / Crospovidone / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Opadry Moisture-Barrier Film Diluent / Superdisintegrant / Glidant / Film-Coating (Engineered specifically to lock out atmospheric moisture, preventing the heavy 500mg amino acid tablet from swelling, cracking, or prematurely degrading before it reaches the patient’s stomach) *Pack Sizes: 10×10 Blisters (Optimized specifically for strict, high-volume chronic hepatology dispensing regimens).
